Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$2.96 USD
+0.16 (5.71%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $2.97 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth NA Momentum NA VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKBA 2.96 +0.16(5.71%)
Will AKBA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Other News for AKBA
Lower Bollinger Band Walk appears for AKBA after 1.06% move
Analysts’ Top Healthcare Picks: ANI Pharmaceuticals (ANIP), Abeona Therapeutics (ABEO)
MACD Bearish Signal Line Cross appears for AKBA after 3.08% move
AKBA forms Bollinger Band Squeeze on September 15
AKBA forms Bollinger Band Squeeze on September 12